PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28489768
OWN - NLM
STAT- In-Process
DA  - 20170510
LR  - 20170518
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 19
DP  - 2017 May
TI  - Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A 
      meta-analysis.
PG  - e6836
LID - 10.1097/MD.0000000000006836 [doi]
AB  - BACKGROUND: This study compares the prevalence rates of comorbidities between
      chronic obstructive pulmonary disease (COPD) and non-COPD control patients
      reported in literature. METHOD: Literature was searched in several electronic
      databases. After the selection of studies by following precised eligibility
      criteria, meta-analyses of odds ratios (ORs) were carried out with subgroup and
      sensitivity analyses under random effects model. RESULTS: Eleven studies
      (47,695,183 COPD and 47,924,876 non-COPD control patients' data) were used for
      meta-analysis. Average age of COPD patients was 66.66 +/- 8.72 years of whom 55.4
      +/- 11.9% were males. The prevalence of cardiovascular comorbidities [OR 1.90,
      95% confidence interval (95% CI) 1.59-2.28; P < .00001], cerebrovascular
      comorbidities (OR 1.84, 95% CI 1.47-2.31; P < .00001), hypertension (OR 1.45, 95%
      CI 1.31-1.61; P < .00001), diabetes mellitus (OR 1.22, 95% CI 1.07-1.38; P =
      .003), neurological and psychiatric disorders (OR 1.78, 95% CI 1.48-2.14; P <
      .00001), gut and renal disorders (OR 1.96, 95% CI 1.43-2.68; P < .00001),
      musculoskeletal disorders (OR 1.51, 95% CI 1.27-1.78; P < .00001), non-COPD
      respiratory comorbidities (OR 2.81, 95% CI 2.52-3.14; P < .00001), and cancer (OR
      1.67, 95% CI 1.25-2.23; P = .0005) were significantly higher in COPD patients
      than in non-COPD controls. CONCLUSION: COPD is associated with significantly
      higher comorbidities than in other diseases that should be taken into
      consideration in COPD control strategies.
FAU - Yin, Hong-Lei
AU  - Yin HL
AD  - aDepartment of Respiratory Medicine, Heilongjiang Provincial Hospital bDepartment
      of Respiratory Medicine, Heilongjiang Electric Power Hospital, Harbin,
      Heilongjiang, China.
FAU - Yin, Shi-Qi
AU  - Yin SQ
FAU - Lin, Qing-Yan
AU  - Lin QY
FAU - Xu, Ying
AU  - Xu Y
FAU - Xu, Hong-Wei
AU  - Xu HW
FAU - Liu, Tao
AU  - Liu T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
PMC - PMC5428602
EDAT- 2017/05/11 06:00
MHDA- 2017/05/11 06:00
CRDT- 2017/05/11 06:00
AID - 10.1097/MD.0000000000006836 [doi]
AID - 00005792-201705120-00035 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 May;96(19):e6836. doi: 10.1097/MD.0000000000006836.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>